Berlin (Reuters) – Novartis reported slightly more optimistic annual forecasts Thursday, citing the strong growth in sales during the second quarter for products such as its Kisqali breast cancer medication.
The Swiss pharmaceutical group said he is now expecting its basic operating profit to increase between 11-14% (‘low teens’) against a previous “two-digit bass” forecast.
The operating profit, excluding exceptional elements, increased by 20% in the second quarter to 5.9 billion dollars (5.09 billion euros), slightly exceeding analysts’ forecasts.
Kisqali quarterly sales jumped 64% to $ 1.2 billion, while those in Kesmpta against multiple sclerosis jumped from $ 1.1 billion.
“Our solid assessment and our confidence in our medium and long -term growth allow us to launch a share of stock to the tune of $ 10 billion as part of our commitment to a balanced distribution of capital,” said VA Narasimhan, CEO of Novartis.
(Written by Miranda Murray; Coralie Lamarque)
Copyright © 2025 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
